[18F]FAPI-42 PET imaging in cancer patients: optimal acquisition time, biodistribution, and comparison with [68Ga]Ga-FAPI-04
- 11 December 2021
- journal article
- research article
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 49 (8) , 2833-2843
Abstract
Purpose [18F]FAPI-42 is a new fibroblast activation protein (FAP)-specific tracer used for cancer imaging. Here, we describe the optimal acquisition time and in vivo evaluation of [18F]FAPI-42 and compared intra-individual biodistribution, tumor uptake, and detection ability to [68Ga]Ga-FAPI-04. Methods A total of 22 patients with various types of cancer received [18F]FAPI-42 whole-body positron emission tomography/computed tomography (PET/CT). Among them, 4 patients underwent PET/CT scans, including an early dynamic 20-min, static 1-h, and static 2-h scans. The in vivo biodistribution in normal organs and tumor uptake were semiquantitatively evaluated using the standardized uptake value (SUV) and tumor-to-background ratio (TBR). Furthermore, both [18F]FAPI-42 and [68Ga]Ga-FAPI-04 PET/CT were performed in 12 patients to compare biodistribution, tumor uptake, and tumor detection ability. Results [18F]FAPI-42 uptake in the tumors was rapid and reached a high level with an average SUVmax of 15.8 at 18 min, which stayed at a similarly high level to 2 h. The optimal image acquisition time for [18F]FAPI-42 was determined to be 1 h postinjection. For tumor detection, [18F]FAPI-42 had a high uptake and could be clearly visualized in the lesions. Compared to [68Ga]Ga-FAPI-04, [18F]FAPI-42 had the same detectability for 144 positive lesions. In addition, [18F]FAPI-42 showed a higher SUVmax in liver and bone lesions (P < 0.05) and higher TBRs in liver, bone, lymph node, pleura, and peritoneal lesions (all P < 0.05). Conclusion The present study demonstrates that the optimal image acquisition time of [18F]FAPI-42 is 1 h postinjection and that [18F]FAPI-42 exhibits comparable lesion detectability to [68Ga]Ga-FAPI-04. Trial registration Chinese Clinical Trial Registry (ChiCTR2100045757).Keywords
Funding Information
- National Natural Science Foundation of China (91949121)
- Applied Basic Research Foundation of Guangdong Province (2021A1515011099)
- Outstanding Youths Development Scheme of Nanfang Hospital, Southern Medical University (2017J010)
- Nanfang Hospital Talent Introduction Foundation of Southern Medical University (123456)
This publication has 29 references indexed in Scilit:
- Development of Fibroblast Activation Protein–Targeted Radiotracers with Improved Tumor RetentionJournal of Nuclear Medicine, 2019
- Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation ProteinJournal of Nuclear Medicine, 2018
- A Tumor-Imaging Method Targeting Cancer-Associated FibroblastsJournal of Nuclear Medicine, 2018
- Imaging fibroblast activation protein to monitor therapeutic effects of neutralizing interleukin-22 in collagen-induced arthritisRheumatology, 2018
- Over-expression of fibroblast activation protein alpha increases tumor growth in xenografts of ovarian cancer cellsActa Biochimica et Biophysica Sinica, 2013
- Fibroblast activation protein is induced by inflammation and degrades type I collagen in thin-cap fibroatheromataEuropean Heart Journal, 2011
- Synthesis of 11C, 18F, 15O, and 13N Radiolabels for Positron Emission TomographyAngewandte Chemie International Edition, 2008
- Tumor-Specific Positron Emission Tomography Imaging in Patients: [18F] Fluorodeoxyglucose and BeyondClinical Cancer Research, 2007
- Dipeptidyl peptidase IV activity and/or structure homologues (DASH) and their substrates in cancerThe International Journal of Biochemistry & Cell Biology, 2004
- Cell-surface glycoproteins of human sarcomas: differential expression in normal and malignant tissues and cultured cells.Proceedings of the National Academy of Sciences, 1988